Mar 28, 2025 8:00 am EDT Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
Mar 27, 2025 8:30 am EDT Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
Mar 26, 2025 8:00 am EDT VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
Mar 25, 2025 9:30 am EDT VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
Mar 21, 2025 8:30 am EDT Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
Mar 20, 2025 8:30 am EDT Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
Mar 13, 2025 8:30 am EDT Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
Mar 11, 2025 8:30 am EDT Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test
Mar 4, 2025 8:30 am EST Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time
